Live tape
Top 8, mentions 7d6,364GOOGL1,414 mentions▲ +0.03META1,309 mentions▲ +0.06NVDA879 mentions▲ +0.09TSLA650 mentions▲ +0.05MSFT590 mentions▲ +0.06AMZN521 mentions▲ +0.05SPY507 mentions▲ +0.03NKE494 mentions▲ +0.04

Equity · Healthcare

NBIX

NASDAQ

Neurocrine Biosciences, Inc.

$157 +1.21% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
Price · Chart
Our own end-of-day closes 36 sessions
$190 $150 6 Jul 10 Sep

The line runs $174 on 6 July through $157 on 10 September, on a scale from $150 to $190. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of NBIX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 36 sessions over that window: $174 on 6 July 2026 through $157 on 10 September 2026.

Market cap $16.0B
P/E (TTM) 23.0
52-week range $123 – $181
Avg volume 113.6K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 10, 2026

NBIX insider trades

SEC Form 4 · last 90 days · newest reported trade 14 Sep 2026
Open-market buys 0
Open-market sells 9
Net sold $6.24M
Non-trade filings 29
Date Insider Type Shares Value
14 Sep 2026 ABERNETHY MATT Chief Financial Officer Sell 2,311 $363K
14 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Sell 826 $130K
09 Sep 2026 BENEVICH ERIC Chief Commercial Officer Sell 2,154 $333K
28 Jul 2026 Norwalk Leslie V Director Sell 1,250 $228K
10 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 4,367 $791K
09 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 8,433 $1.51M
09 Jul 2026 Lippoldt Darin Chief Legal Officer Sell 10,000 $1.80M
08 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 2,737 $489K
07 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 3,401 $607K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Sep 2026 ABERNETHY MATT Chief Financial Officer Award 5,020
11 Sep 2026 ABERNETHY MATT Chief Financial Officer Tax withheld 2,709 $423K
11 Sep 2026 BENEVICH ERIC Chief Commercial Officer Award 6,275
11 Sep 2026 BENEVICH ERIC Chief Commercial Officer Tax withheld 3,386 $529K
11 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Award 3,587
11 Sep 2026 Boyer David W. Chief Corp. Affairs Officer Tax withheld 1,936 $302K
11 Sep 2026 Cooke Julie Chief Human Resources Officer Award 3,587
11 Sep 2026 Cooke Julie Chief Human Resources Officer Tax withheld 1,936 $302K
11 Sep 2026 Delaet Ingrid Chief Regulatory Officer Award 4,483
11 Sep 2026 Delaet Ingrid Chief Regulatory Officer Tax withheld 2,419 $378K
11 Sep 2026 GORMAN KEVIN CHARLES Director Award 14,343
11 Sep 2026 GORMAN KEVIN CHARLES Director Tax withheld 7,839 $1.22M

Showing the 12 most recent of 29 compensation filings in this window. The figures above count all of them.

NBIX reported financials

SEC EDGAR XBRL

NBIX reported revenue of $2.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $478.6M.

Figure Reported Period
Revenue $2.9B 31 Dec 2025 fiscal year
Net income $478.6M 31 Dec 2025 fiscal year
Diluted EPS $4.67 31 Dec 2025 fiscal year
Total assets $5.4B 30 Jun 2026 at period end
Total equity $3.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

NBIX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.39 —
31 Mar 2026 Q1 2026 $1.91 —
31 Dec 2025 FY 2025 $4.67 —
30 Sep 2025 Q3 2025 $2.04 —
30 Jun 2025 Q2 2025 $1.06 —
31 Mar 2025 Q1 2025 $0.08 —
31 Dec 2024 FY 2024 $3.29 —
30 Sep 2024 Q3 2024 $1.24 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

NBIX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a NBIX position for the quarter ended 30 Jun 2026 — a combined $1.6B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) −22.7% shares 3,818,037 $643.5M
Renaissance Technologies Held (±25%) −3.4% shares 2,335,897 $393.7M
Two Sigma Investments Trimmed −32.2% shares 2,076,260 $349.9M
Man Group Added +44.5% shares 601,019 $101.3M
Marshall Wace Trimmed −46.8% shares 270,754 $45.6M
Bridgewater Associates Added +38.8% shares 205,677 $34.7M
Fisher Asset Management Held (±25%) +10.5% shares 135,104 $22.8M
Citadel Advisors Trimmed −79.5% shares 11,863 $2.0M
Millennium Management Trimmed −99.1% shares 11,585 $2.0M
D. E. Shaw & Co. Trimmed −93.7% shares 5,599 $944K

Source: SEC EDGAR 13F filings

NBIX fails-to-deliver

SEC CNS data

On 11 Sep 2026, 1,221 shares of NBIX failed to deliver (about $191K).

Settlement date Shares failed Notional % of shares out
11 Sep 2026 1,221 $191K 0.001%
09 Sep 2026 11 $2K <0.001%
08 Sep 2026 19 $3K <0.001%
28 Aug 2026 1,609 $251K 0.002%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in NBIX

STOCK Act disclosures

The most recent congressional trade disclosed in NBIX is a sale by Lisa C. McClain (house, MI), dated 17 Jun 2025.

Date Member Type Amount
17 Jun 2025 filed 13 Aug 2025 Lisa C. McClain house · Republican–MI Sale $1K–$15K
11 Jun 2025 filed 13 Aug 2025 Lisa C. McClain house · Republican–MI Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures